Published 28th June 2016

Abingdon Health signs global distribution agreement with Sebia

Imperial Innovations notes that its portfolio company, Abingdon Health, an in-vitro diagnostic group has alongside Sebia, the world leader in medical diagnostics by electrophoresis, announced that they have entered into a multi-year, exclusive, global distribution agreement. The deal allows Sebia to add Abingdon Health’s Seralite®-FLC Dual Kappa and Lambda serum lateral flow immunoassay to its worldwide offering. The financial terms of the agreement have not been disclosed.

Seralite®-FLC is the most recent generation of rapid, smart and easy-to-operate test for the quantitative measurement of free kappa and free lambda light chains in blood. Serum free light chain (sFLC) testing is prescribed to help detect, diagnose and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, and to monitor the effectiveness of treatments. The test is aimed at clinical laboratories with a small to medium-sized workload for sFLC test requests as well as at clinical laboratories sending requests to referral laboratories, which might result in some countries in delays in receiving patients’ results. It brings superior analytical performance along with cost effectiveness and flexibility.

The agreement with Abingdon Health will enable Sebia to provide a comprehensive offering for the diagnosis and monitoring of multiple myeloma and associated conditions, addressing the emerging demand from clinical labs for improving responsiveness in their daily routine and in patient care.

The Seralite® – FLC assay was initially developed via a joint venture with Abingdon Health Ltd and the University of Birmingham. Commercial availability of this quality product is the result of a combination of scientific and clinical expertise at Birmingham University together with Abingdon Health’s product development and manufacturing expertise. The University of Birmingham has been involved in a large number of scientific publications on serum free light chain measurement over the past decade. It has recently submitted several articles on Seralite®-FLC. The partnership with Sebia will improve patient’s access on a global scale to Seralite®-FLC.

“Since its creation in 1967 Sebia has had a strong focus on myeloma. Its leadership position in this field comes from a continuous flow of innovation to help laboratories in their daily activities diagnosing and monitoring this pathology,” said Benoit Adelus, Sebia's chairman and CEO. “The partnership with Abingdon Health will give the opportunity for small to mid size labs around the world to perform the FLC test, on a high quality, simple device.”

“We are delighted to partner with Sebia in the global distribution of Serum Seralite®-FLC. Sebia’s global reach and market leadership in the provision of electrophoresis testing makes it the perfect partner to launch our new product worldwide,” said Chris Yates, CEO of Abingdon Health. “We believe the combination of Abingdon Health and Sebia’s products provides customers with the complete solution for the testing of multiple myeloma [in serum].”

Sebia is the world leader in multiple myeloma diagnosis and monitoring by electrophoresis, with 70% of the worldwide protein electrophoresis market. It has a strong network of specialized commercial and scientific organizations in 120 countries. These help the company’s customers with their electrophoresis work on a daily basis.

Over the next couple of months Sebia will supervise the global launch of Seralite-FLC across all of the company’s sales channels. The commercial team at Abingdon Health will also support this campaign. Sebia will distribute the product worldwide, except in Belgium, the Netherlands and Luxembourg.